Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents. - Wikidata - awgldk - TriplyDB

Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents.

Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents.

http://www.wikidata.org/entity/Q42008120

about

Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus Current and Future Considerations for the Treatment of Hospital-Acquired Pneumonia Update on the emerging role of telavancin in hospital-acquired infections Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults.Telavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience.Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.New antibiotics for bad bugs: where are we?Telavancin: a review of its use in patients with nosocomial pneumonia.Efficacy of telavancin, a lipoglycopeptide antibiotic, in experimental models of Gram-positive infection.The times they are a-changin': new antibacterials for skin and skin structure infections.A review of telavancin activity in in vitro biofilms and animal models of biofilm-associated infections.Pharmacodynamics, pharmacokinetics and clinical efficacy of telavancin in the treatment of pneumonia.Successful salvage treatment of native valve Enterococcus faecalis infective endocarditis with telavancin: two case reports.Assessment of Minimum Inhibitory Concentrations of Telavancin by Revised Broth Microdilution Method in Phase 3 Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia Clinical Isolates.Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011-2013) using a revised broth microdilution testing method: redefining the baseline activity of telavancin.Telavancin for refractory methicillin-resistant Staphylococcus aureus bacteremia and infective endocarditis.Telavancin in vitro activity against a collection of methicillin-resistant Staphylococcus aureus isolates, including resistant subsets, from the United States In vitro activity of telavancin compared with vancomycin and linezolid against Gram-positive organisms isolated from cancer patients.In Vitro Synergy of Telavancin and Rifampin Against Enterococcus faecium Resistant to Both Linezolid and Vancomycin.Quality control MIC ranges used for telavancin with application of a revised CLSI reference broth microdilution method.

P2860

Q27027412-CE9183D7-F173-4CED-BB1D-2E48E9C04089 Q28071882-ED505495-F126-4B9D-A9B1-F0BA61EE8740 Q28083522-E4D82465-D0A9-451E-B08A-D26760EC77D7 Q33657212-323AA024-1C7F-42FA-9AC9-940A760949F3 Q34677611-AF6F0EBD-81CF-4EA1-909F-F8D533AFAA88 Q35678198-4949FD26-DE9A-4EA5-B949-659256DE66A6 Q38132217-EF8EB09A-6FF3-49F7-BD6B-45970833F4FF Q38159966-773ACAD2-D442-412F-8D2F-243B92014206 Q38266421-32A4DDDD-309B-40B8-8A59-3EE4E1B20E65 Q38438503-CA4FC646-3AC8-4FF0-839C-39FFCF5A59CF Q38530316-A5380715-EA2C-4B55-AC28-E6088D98B131 Q38829519-F8BCA511-BA29-49F2-984A-A478A8232111 Q40294018-68E89562-0C38-4D82-9CD9-57084BD36799 Q40513210-C7617A09-1AEA-48DC-9B17-ED4B3E289399 Q41172790-1ABBD76D-7658-4CC6-B269-342172A51C73 Q41445957-B5D3ABA2-21F1-406B-BCA1-5FC429063D43 Q41561992-E47573DD-9E4C-489D-A063-A98BBC32F06E Q42215430-0D7C4E32-5328-492F-B0C0-94F24E643EFA Q42218341-4BDEA17A-654A-450D-A281-6B9E3BD70FF4 Q43125915-8EC6513D-3B90-40FF-8D83-AE7CCB3C53BA

P2860

Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents.

http://www.wikidata.org/entity/Q42008120

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Worldwide appraisal and update ...... athogens from five continents.

@en

Worldwide appraisal and update

@nl

type

label

Worldwide appraisal and update ...... athogens from five continents.

@en

Worldwide appraisal and update

@nl

prefLabel

Worldwide appraisal and update ...... athogens from five continents.

@en

Worldwide appraisal and update

@nl

P1433

Q42008120-D590AFAB-9780-41D9-814F-5CCB6184A884

P1476

Q42008120-FD1DC9F4-7752-49A7-A51A-F9771760A0BE

P2093

Q42008120-65113CD5-047E-4B07-8830-C8BB3EDE69C0

Q42008120-7A4A234C-0BD3-4C33-9CFF-0DC39C331F99

Q42008120-C81CFC8C-3755-4F62-8B53-60E961FB009F

P2860

Q42008120-2A7E732A-0EE1-4460-9D5F-AB7E4FB863CF

Q42008120-2C98AD4C-DE4D-4284-9670-E7EC73D4C804

Q42008120-2E5C7095-EE30-493F-A42B-A6E9D0E1E81E

Q42008120-2EE2878A-01D1-4F33-ACBA-EBE6639F493D

Q42008120-87E0BC0B-4134-4D9B-AD8F-A58529BA4826

Q42008120-B3C32029-14D7-4471-8285-FDE6A51AB235

Q42008120-B98B3EDD-7ADF-4CE2-9FE8-772266853172

Q42008120-C82D1E22-CE46-4F54-BD4B-706F7338E670

Q42008120-EEE18DBD-12C4-4079-B43E-27E3435F859D

P304

Q42008120-7091E334-7825-4790-8BC4-7A17B075BB25

P31

Q42008120-23B6A6AC-29A6-4A08-B012-7AF1EB3412F8

P356

Q42008120-B67DF148-D7E5-4132-82E9-326551E2EED9

P407

Q42008120-9269B11C-980F-4D3F-BB39-4C0E7FC7A20F

P433

Q42008120-BABC78AF-B8A4-4899-846F-425FA159E603

P478

Q42008120-DCF56A9D-3000-4C5F-ADED-E8353FAAD6A7

P50

Q42008120-3405E5C6-5900-4621-9775-BB9F3116CB75

P577

Q42008120-9CA8963C-5702-4A9A-93D7-70509BA2C461

P698

Q42008120-5D916FB6-24BF-4DF9-A033-BE0953DE75F2

P921

Q42008120-2A3AE4CF-8589-4017-A347-3BA2A58D670F

Q42008120-48040FA5-8B1D-45E2-B68B-39F1DE170997

P932

Q42008120-28378DA4-7DCA-44D3-93F6-C929BFA0EC50

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Worldwide appraisal and update ...... athogens from five continents.

@en

P2093

David J Farrell

http://www.w3.org/2001/XMLSchema#string

Rodrigo E Mendes

http://www.w3.org/2001/XMLSchema#string

Ronald N Jones

http://www.w3.org/2001/XMLSchema#string

P2860

Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus

In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates

Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.

Clinical activity of anti-Gram-positive agents against methicillin-resistant Staphylococcus aureus.

In vitro activity of telavancin against resistant gram-positive bacteria.

Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies.

Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.

Update on the telavancin activity tested against European staphylococcal clinical isolates (2009-2010).

In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative.

P304

3999-4004

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00011-12

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-04-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22508304

http://www.w3.org/2001/XMLSchema#string

P921

Gram-positive bacteria

P932

3393449

http://www.w3.org/2001/XMLSchema#string